Extracellular vesicles (EVs), and exosomes in particular, are transitioning from academic research to biotech development and onwards towards the clinic.
Close to 50 EV companies have already emerged, particularly since 2017, with growing support from investors. These companies are focusing on both therapeutic and diagnostic applications.
The emerging exosome biotech companies have a surprisingly diverse set of strategies which are shaping the medical and commercial future of the nascent exosome field. In the therapeutic field, exosomes derived from plants, human and animal biofluids, cultured cells as well as synthetic exosome mimetics are being developed. In diagnostics, a wide variety of disease targets and detection methods are being employed.
These companies’ activities are prompted by extraordinary medical potential: Exosomes are hollow lipid spheres actively generated within cells. As well as lipids, they contain neatly packaged protein and nucleic products which reflect the unique identity and activity of the cell in which they were made.
To receive a link to the full 27-page report, which includes summaries of activities at all companies as well as an overview of ongoing exosome clinical trials, please provide your email address.